Litcius/Paper detail

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Zefei Jiang, Quchang Ouyang, Tao Sun, Qingyuan Zhang, Yuee Teng, Jiuwei Cui, Haibo Wang, Yongmei Yin, Xiaojia Wang, Xin Zhou, Yongsheng Wang, Gang Sun, Jingfen Wang, Lili Zhang, Jin Yang, Jun Qian, Min Yan, Xinlan Liu, Tienan Yi, Ying Cheng, Man Li, Aimin Zang, Shusen Wang, Chuan Wang, Xinhong Wu, Jing Cheng, Hui Li, Ying Lin, Cuizhi Geng, Kangsheng Gu, Chunwei Xie, Huihua Xiong, Xiaohong Wu, Junlan Yang, Qingshan Li, Yiding Chen, Fanfan Li, Anqin Zhang, Yongqiang Zhang, Yudong Wu, Jianyun Nie, Qiang Liu, Kun Wang, Xueli Mo, Lilin Chen, Yueyin Pan, Peifen Fu, Helong Zhang, Danmei Pang, Yuan Sheng, Yunwei Han, Hongxia Wang, Shundong Cang, Xianming Luo, Wenbo Yu, Rong Deng, Chaoqiang Yang, Patricia Keegan

2024Nature Medicine114 citationsDOI

Topics & Concepts

MedicineHazard ratioInternal medicineMetastatic breast cancerTriple-negative breast cancerClinical endpointInterim analysisPlaceboAdverse effectProgression-free survivalPopulationConfidence intervalOncologyBreast cancerRandomized controlled trialChemotherapyCancerGastroenterologyPathologyEnvironmental healthAlternative medicineCancer Immunotherapy and BiomarkersAdvanced Breast Cancer TherapiesLung Cancer Treatments and Mutations
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial | Litcius